SP SAP Drug Development

Drug Development Update

Chronic pain conditions are often caused by ongoing disease states or tissue damage that create sensitization of both the primary afferents (nerves that convey impulses from the outer part of the body) and spinal cord neurons. This sensitization results in a persistent increased sensitivity to both noxious (hyperalgesia) and non-noxious (allodynia) stimuli. Many persistent pain …

Drug Development Update Read More »

Advanced Targeting Systems Awarded 2.4 Million Dollar SBIR Grant to Develop Revolutionary Chronic Pain Drug

San Diego, CA, October 7, 2003 – Advanced Targeting Systems, Inc. announced today that it has received a Small Business Innovative Research (SBIR) grant from the National Institute of Mental Health (NIMH) under the program announcement for pharmacologic agents and drugs to combat mental disorders. The three-year, $2.4 million award is a continuation of Phase …

Advanced Targeting Systems Awarded 2.4 Million Dollar SBIR Grant to Develop Revolutionary Chronic Pain Drug Read More »

Funding Awarded for SBIR Phase II Grant

On February 1, 2003 ATS was awarded an $800,000 grant from the National Institutes of Health, National Institute of Mental Health. This three-year grant will support the creation of monoclonal antibodies to the extracellular domains of G protein-coupled receptors. These receptors play an important role in all aspects of human health, reflecting their widespread presence …

Funding Awarded for SBIR Phase II Grant Read More »

Safety Studies Begin

Early last month (March 2001), Advanced Targeting Systems (ATS) received funding from the National Institute of Mental Health (NIMH) to begin toxicology/safety studies of Substance P-Saporin (SP-SAP), a potential therapeutic for the treatment of chronic pain. The studies will be completed under the direction of three scientists who are experts in their respective fields. Dr. …

Safety Studies Begin Read More »